Neurology news

• Alzheimer's

• ADHD

• Anxiety

• Autism

• Brain tumors

• Clinical trials

• Depression

• Epilepsy

• Migraine

• MS

• Neurogenetics

• Neuroimaging

• Neuropathy

• Pain

• Parkinson's

• Seizures

• Sleep

• Stroke

• Tremor

MULTIPLE SCLEROSIS

Arbaclofen placarbil (AP):

May be effective in reducing spasticity with fewer doses.  The ongoing study is funded by XenoPort, Inc.

Link: http://www.xenoport.com/research_development/ap.htm

Phase 3 Trial for Alemtuzumab

Phase 3 trial of Alemtuzumab versus interferon beata-1a seems to be positive with significant reduction in relapses in patients taking this agent versus Rebif. 

Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I) trial were presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).  This substance helps block the effect and number of two blood cell types called the monocytes and lymphocytes thereby reducing multiple sclerosis attacks.

Home    Services    News    About us    Neuro pictures       Links    Contact us